eaza LABORATORY

The World Health Organization's Report on Malaria in Nigeria 2022 shows that Malaria is a major public health concern in Nigeria, with an estimated 68 million cases and 194,000 deaths due to the disease in 2021.

Nigeria is the most populous country in Africa with a population of 225 million in 2021, increasing from 123 million people in 2000. Nigeria had 68 million cases in 2021 accounting for 27% of the global burden, and 28% of the burden in the WHO African Region. WHO also estimates that the severe form of malaria has led to 194,000 deaths in 2021 alone, about 80% of these in children under the age of 5 years. This accounts for 31% of all malaria deaths globally and 40% in the WHO African Region.

Like other high burden countries in the WHO African region, and despite the best efforts of the country and its partners, the disruptions to essential malaria services in Nigeria led to additional 480,000 malaria cases and 10,000 malaria deaths according to WHO estimates. In 2021, about 37% of children under the age of 5 years still do not receive care within two weeks of fever onset.

Only a quarter of all children with fever get tested, and among those who seek care, only 39% are tested. Despite recent improvements, MALARIA PARASITOLOGICAL DIAGNOSIS REMAINS LOW IN NIGERIA, LEADING TO INAPPROPRIATE TREATMENT OF PATIENTS AND IRRATIONAL USE OF MALARIA DRUGS WHICH ALSO CONTRIBUTES TO THE RAPID INCREASE IN ANTI-MALARIA DRUG RESISTANT PLASMODIUM STRAIN ACROSS NIGERIA. THE LOW LEVEL OF DIAGNOSIS ALSO UNDERMINES THE QUALITY AND RELIABILITY OF MALARIA DATA REPORTED THROUGH THE HEALTH SYSTEM.

In addition to consultation fees at public health facilities, the high use of the private sector highlights that there is a high out-of-pocket expenditure by households on fever, and by extension on malaria care. Among low-income communities, such expenditure could be catastrophic and plunge them deeper into poverty impairing their ability to seek further health care. 

Data from household surveys show that malaria prevalence in children, assessed via microscopy and rapid diagnostic test (RDT), dropped from 27% and 45% in 2015 to 22% and 40% in 2021, respectively.

In May 2022, the country convened its local and external stakeholders for a ‘‘data deep-dive’’ week in Abuja to explore the progress the country has made in the use of strategic information to drive impact against malaria. One of the recommendations from this meeting was a request by the Nigeria National Malaria Elimination Programme (NMEP) to WHO to develop state-level malaria profile reports. The report presents an overview of the malaria situation across all States in Nigeria, focusing on population demographics, malaria interventions, climate and disease burden. For each State, the report presents trends in population, rainfall patterns, intervention coverage and use, malaria prevalence and incidence.

While Nigeria has been at the forefront of using subnational data for effective malaria planning and implementation, the increasing budget constraints will require further prioritization. In addition, considerable increase in domestic funding is required. Synergies with other health programmes through improved integration that will likely increase efficiency of implementation is required.

Pitch Demo Video

eaza LABORATORY aims to complement the activities and policies of the Nigeria National Malaria Elimination Programme (NMEP) by setting-up and providing an Artificial Intelligence software to help accurately and quickly capture and confirm Malaria cases by image analysis with pre-trained models at the 774 local government areas across the 36 States in Nigeria. Also, capture, monitor, and provide real-time data and reports on the socioeconomic challenges of Malaria patients at the local government level by asking specific questions tailored to capture quantitative data from patients when they visit any healthcare facility where eaza LABORATORY is implemented, and provide reports and quantitative data on the environmental and socio-political changes that contribute to climate change (these data will be captured through collaboration with relevant institutions such as the National Environmental Standards and Regulations Enforcement Agency, National Bio-safety Management Agency, Forestry Research Institute of Nigeria, National Oil Spill Detection and Response Agency, National Emergency Management Agency, and Nigeria Hydrological Services) and how these factors directly affect the incidence, increase and prevalence of Malaria in Nigeria at each State-levels with focus on quantitative and qualitative data from each local government level, and ensure that this data is readily available and accessible by policy-makers who can use this information for strategic and quick response policy to the challenges posed by Malaria in the 774 local government areas in Nigeria.

eaza LABORATORY is an AI-powered Laboratory Information Management System software web application designed to assist tropical laboratory use image analysis to accurately and quickly diagnose tropical diseases that are of clinical importance such as malaria. With our software, there will be no need for a specialized skillset in the Microscopical identification and detection of malaria parasites and other clinically important tropical parasite that posed a huge burden on LMIC countries such as Nigeria from clinically stained blood samples of suspected patients. Only a high-resolution image of the stained blood sample is required and uploaded onto eaza LABORATORY, and the specific tropical disease to be elucidated and identified is selected prior to prompting AI analysis of the uploaded image to confirm presence of parasite, count parasite, and confirm positive test using expert pre-trained models.

Reduce financial burden posed by consultation fees at public tertiary healthcare facilities, and the high use of the private sector which result in high out-of-pocket expenditure by households on fever, and by extension on malaria care. Among low-income communities, such expenditure could be catastrophic and plunge them deeper into poverty impairing their ability to seek further health care.

We are proposing a new approach to the detection and reporting of tropical diseases by ensuring accurate data, readily available data for policymaking and reporting, and giving policymakers the ability to track, monitor, and predict the potential outbreak and prevalence of tropical diseases in LMIC countries. Ensure that Nigeria continues to be at the forefront of using grassroot data for effective malaria planning and implementation, reduce budget constraint, create synergies with other health programmes.

Our solution is targeted at Low- and Middle-Income Countries were the incidence and burden of malaria and other tropical disease is very high. Currently, our pilot solution is targeted at helping over 68 million Nigerians estimated by the World Health Organization to be suffering from Malaria. Our grassroot approach, we see us implement our solutions across the entire 774 local government areas in Nigeria, thus, ensuring that people who need this solution can access it, without the financial burden of visiting public tertiary healthcare institutions or highly expensive private healthcare facilities.

Malaria is endemic in Nigeria and is a leading cause of death and disease in many countries (LMIC). Young children and pregnant women are the most affected groups.

While Governments of the world and other institutions are focused on prioritizing women and children's health, socioeconomic challenges still make these social group vulnerable and exposures to them many health challenges and diseases.  

Many women and children in remote (grassroot and local government levels) and underserved communities lack access to basic healthcare services, including proper diagnostic facilities and timely medical interventions.

Educational opportunities for children in these communities are often limited due to inadequate school facilities, a shortage of qualified teachers, and a lack of essential educational resources. making them more exposure to diseases.

Malnutrition and health disparities contribute to increased susceptibility to various diseases, including malaria, which poses a significant threat to the well-being of both women and children.

The eaza LABORATORY solution can effectively address the needs of this vulnerable population by:

1. Improving Diagnostic Accuracy: By providing an AI-powered diagnostic tool for the accurate and timely detection of diseases like malaria, the solution ensures that women and children receive prompt and effective medical interventions.

2. Enabling Data-Driven Policy Decisions: Real-time data and comprehensive reports generated by the software can facilitate evidence-based policymaking, leading to the implementation of targeted interventions that address the specific health and educational needs of underserved women and children.

3. Promoting Preventive Healthcare: The software's capabilities can contribute to preventive healthcare measures by identifying environmental factors contributing to disease prevalence, thereby enabling the implementation of proactive strategies to mitigate these risks.

4. Capacity Building and Training: The solution can incorporate educational modules and training programs aimed at enhancing the capacity of healthcare professionals in underserved areas, enabling them to provide improved healthcare services to women and children.

By prioritizing the specific needs of underserved women and children in Nigeria, the eaza LABORATORY software can play a pivotal role in bridging the existing healthcare and educational gaps, thereby contributing to the overall improvement of their quality of life and well-being.

As the Team Lead, I can categorically state that our team closely align with the communities we aim to serve, our proximity and understanding of their needs are fundamental to the design and delivery of the eaza LABORATORY solution. Our approach prioritizes community engagement and collaboration, ensuring that the software development process is guided by the insights, ideas, and priorities of the communities we seek to empower. Here are some key points that reflect our commitment to community involvement:

1. Community Integration: We have established strong relationships within the target communities, actively engaging with local leaders, healthcare workers, and community members to gain firsthand insights into their challenges, needs, and priorities. Our team regularly participates in community events, conducts focus groups, and organizes interactive workshops to foster a deeper understanding of the community's healthcare and educational requirements.

2. Cultural Sensitivity: Recognizing the significance of cultural nuances and local practices, we have integrated culturally sensitive approaches into our solution design. By respecting the values and traditions of the communities, we ensure that the eaza LABORATORY software aligns with their cultural norms, preferences, and expectations, thereby fostering greater acceptance and adoption.

3. User-Centric Design: Our development process prioritizes user-centric design principles, integrating user feedback and iterative testing to ensure that the software meets the specific needs and preferences of the target population. Through participatory design workshops and usability testing sessions, we actively involve community members in the decision-making process, allowing them to contribute their perspectives and preferences to the software's features and functionalities.

4. Capacity Building Initiatives: To empower the communities we serve, we have initiated capacity building programs that provide training and educational opportunities for local healthcare professionals and community members. These programs aim to enhance the community's understanding of the software's capabilities, fostering a sense of ownership and enabling them to actively participate in the sustainable utilization of the eaza LABORATORY solution.

5. Sustainable Partnerships: Our team has fostered sustainable partnerships with local organizations, NGOs, and governmental agencies to ensure the long-term viability and impact of the eaza LABORATORY solution. By collaborating with these stakeholders, we are able to leverage their expertise, resources, and local knowledge to create a holistic and inclusive approach that addresses the multifaceted challenges faced by the communities.

Through our ongoing commitment to community engagement, cultural sensitivity, and sustainable partnerships, we are dedicated to designing and implementing the eaza LABORATORY solution in a manner that is truly reflective of the needs, aspirations, and priorities of the communities we serve, particularly women and children.

The eaza LABORATORY solution approaches the challenge of malaria detection and healthcare data analysis in a novel and impactful manner, leveraging cutting-edge AI technology to revolutionize diagnostic capabilities and inform evidence-based policy decisions. Our innovative approach introduces several key features that could catalyze broader positive impacts and potentially reshape the healthcare landscape, not just in Nigeria but across the broader global health sector:

1. Advanced AI-Driven Diagnosis: By harnessing the power of sophisticated AI algorithms and image analysis techniques, the eaza LABORATORY solution significantly enhances the accuracy and efficiency of malaria parasite detection, surpassing the limitations of conventional diagnostic methods. This advanced approach not only ensures prompt and reliable diagnosis but also sets a new standard for diagnostic accuracy in the field of tropical disease detection.

2. Real-Time Data Reporting and Analysis: The software's capability to provide real-time data and comprehensive reports on the socioeconomic and environmental factors influencing disease prevalence could catalyze broader positive impacts by enabling policymakers, public health agencies, and research institutions to make data-driven decisions and implement targeted interventions. This holistic approach to data analysis has the potential to shape public health policies and initiatives, fostering a more proactive and effective approach to disease prevention and management.

3. Technology Transfer and Knowledge Sharing: Our solution is designed with the intent to foster technology transfer and knowledge sharing across the healthcare sector. By incorporating open-access modules and educational resources, the eaza LABORATORY solution can serve as a catalyst for broader knowledge dissemination, empowering healthcare professionals and researchers to leverage AI technology for improved disease detection and analysis. This approach has the potential to foster collaboration and innovation within the global health community, leading to the emergence of new standards and best practices in disease diagnosis and public health management.

4. Market Transformation and Innovation: The introduction of the eaza LABORATORY solution has the potential to catalyze market transformation by spurring increased investment and innovation in AI-driven healthcare technologies. As the software sets a new precedent for advanced diagnostic capabilities and data-driven disease analysis, it could incentivize other players in the healthcare technology sector to invest in similar groundbreaking solutions. This heightened competition and innovation are likely to drive market growth, leading to the development of a diverse range of AI-powered healthcare solutions that can address various healthcare challenges globally.

By introducing a comprehensive solution that integrates advanced AI technology with real-time data analysis and reporting, the eaza LABORATORY software not only contributes to the immediate improvement of disease detection and management but also fosters a transformative impact on the broader healthcare ecosystem, catalyzing innovation, collaboration, and improved healthcare outcomes on a global scale.

The eaza LABORATORY solution is intricately aligned with the United Nations Sustainable Development Goal 3 (SDG 3) of ensuring good health and well-being for all. Through its comprehensive approach to disease detection, data analysis, and policy implementation, the solution actively contributes to the attainment of several specific targets outlined within SDG 3. Here's how the eaza LABORATORY solution addresses and plans to address the UN Sustainable Development Goal 3:

1. Combatting Malaria and Other Tropical Diseases: By leveraging AI-powered diagnostic capabilities, the eaza LABORATORY solution plays a pivotal role in combatting diseases such as malaria, thereby contributing to the reduction of global disease burden as outlined in SDG 3.3. Its ability to accurately detect and analyze malaria parasites in blood samples facilitates early diagnosis and prompt treatment, leading to improved health outcomes and a significant reduction in mortality rates associated with these diseases.

2. Enhancing Healthcare Infrastructure and Capacity: The solution's emphasis on real-time data reporting and analysis supports the improvement of healthcare infrastructure and capacity, aligning with SDG 3.8. By providing valuable insights into disease prevalence, environmental factors, and socio-economic determinants of health, the eaza LABORATORY software empowers policymakers and healthcare professionals to make informed decisions and implement targeted interventions, ultimately strengthening healthcare systems and enhancing access to quality healthcare services in underserved communities.

3. Promoting Preventive Healthcare and Education: Through its emphasis on data-driven insights and knowledge sharing, the eaza LABORATORY solution contributes to the promotion of preventive healthcare and education, as emphasized in SDG 3.4 and 3.7. By providing comprehensive reports on the environmental factors contributing to disease prevalence, the solution enables the implementation of proactive strategies to mitigate health risks, while its educational modules and capacity-building initiatives foster greater awareness and understanding of disease prevention and management among healthcare professionals and community members.

4. Promoting Universal Health Coverage: The eaza LABORATORY solution supports the goal of achieving universal health coverage, as outlined in SDG 3.8, by facilitating access to accurate and timely diagnostic services, particularly in underserved communities where healthcare infrastructure is limited. By empowering healthcare providers with the tools and knowledge necessary for effective disease detection and management, the solution contributes to the realization of equitable access to quality healthcare services, thereby ensuring that no one is left behind in the pursuit of good health and well-being.

Through its multifaceted approach to disease detection, data analysis, and capacity building, the eaza LABORATORY solution actively contributes to the realization of SDG 3, fostering improved health outcomes and well-being for communities, particularly in regions where access to quality healthcare services remains a challenge.

The eaza LABORATORY solution harnesses advanced AI components to enable accurate and efficient detection of malaria parasites through image analysis of stained blood sample specimens. The software incorporates several key AI technologies, including:

1. Deep Learning Algorithms: The solution utilizes deep learning algorithms, such as convolutional neural networks (CNNs), to analyze and interpret digital images of stained blood samples. These algorithms are trained to identify and classify malaria parasites based on distinct patterns and features within the images, enabling the software to provide precise and reliable diagnostic results.

2. Image Processing Techniques: Advanced image processing techniques, including feature extraction, image segmentation, and pattern recognition, are employed to enhance the accuracy and efficiency of malaria parasite detection. These techniques enable the software to identify subtle variations in the morphology of malaria parasites, ensuring the precise identification and localization of infected cells within the blood samples.

3. Data Analytics and Pattern Recognition: The solution incorporates sophisticated data analytics and pattern recognition capabilities to analyze large datasets of patient information, environmental data, and disease prevalence statistics. By identifying patterns and correlations between environmental factors, disease incidence, and patient demographics, the software generates valuable insights that facilitate a comprehensive understanding of the socio-economic and environmental determinants of disease prevalence.

4. Machine Learning for Data Interpretation: Machine learning models are integrated into the software to facilitate the interpretation of complex data sets, enabling the identification of trends and predictive patterns related to disease outbreaks, environmental changes, and socio-economic factors. These models continuously learn from new data inputs, thereby enhancing the software's predictive capabilities and enabling proactive decision-making in disease management and prevention strategies.

Regarding data acquisition, our plan involves leveraging a combination of curated and proprietary data sets. We aim to collaborate with healthcare institutions, research organizations, and public health agencies to access high-quality, validated data sets related to malaria prevalence, patient demographics, environmental factors, and disease risk indicators. Additionally, we are committed to implementing stringent data curation and quality assurance protocols to ensure the integrity and reliability of the data used to train and validate the AI components of the eaza LABORATORY solution. This approach will enable us to build robust and accurate AI models that can effectively analyze and interpret complex data sets, ultimately enhancing the software's diagnostic capabilities and its potential impact on disease detection and management.

Ensuring the ethical and responsible use of AI is a paramount consideration in the development and implementation of the eaza LABORATORY solution. To address potential risks and uphold ethical standards, our team has implemented a comprehensive framework that encompasses the following key measures:

1. Privacy and Data Security Protocols: We have established stringent privacy and data security protocols to safeguard sensitive patient information and ensure compliance with international data protection regulations, including the General Data Protection Regulation (GDPR) and relevant local data protection laws. By implementing robust encryption methods, access controls, and anonymization techniques, we prioritize the confidentiality and integrity of patient data, thereby mitigating potential privacy and security risks.

2. Ethical AI Development Guidelines: Our team adheres to ethical AI development guidelines that prioritize transparency, fairness, and accountability in the software's algorithms and decision-making processes. We have incorporated measures to identify and mitigate algorithmic biases, ensuring that the AI components of the eaza LABORATORY solution do not perpetuate discriminatory practices or reinforce existing inequalities within healthcare systems.

3. Risk Assessment and Mitigation Strategies: We have conducted comprehensive risk assessments to identify and address potential risks associated with the solution's implementation, including regulatory compliance, data breaches, and algorithmic biases. By proactively identifying these risks, we have implemented robust mitigation strategies that include continuous monitoring, regular audits, and compliance checks to ensure the ethical and responsible use of AI throughout the software's lifecycle.

4. Stakeholder Engagement and Education: Our team actively engages with stakeholders, including healthcare professionals, policymakers, and community members, to foster greater awareness and understanding of the ethical implications and responsibilities associated with AI-driven healthcare solutions. Through educational workshops, training programs, and transparent communication channels, we aim to promote a culture of ethical awareness and responsibility, ensuring that all stakeholders are well-informed and actively involved in the ethical deployment of the eaza LABORATORY solution.

5. Regulatory Compliance and Policy Adherence: We are committed to adhering to relevant regulatory frameworks and industry standards governing the use of AI in healthcare. Our team closely monitors developments in data protection regulations and healthcare policies, ensuring that the eaza LABORATORY solution remains compliant with evolving legal and ethical requirements. We prioritize transparency in our operations, maintaining open communication with regulatory authorities and seeking their guidance to ensure that our solution aligns with the highest ethical and legal standards.

Through our proactive approach to risk assessment, ethical guidelines, stakeholder engagement, and regulatory compliance, we are dedicated to promoting the ethical and responsible use of AI in healthcare, mitigating potential risks, and upholding the integrity and trustworthiness of the eaza LABORATORY solution as it scales and makes a meaningful impact on healthcare outcomes.

Our impact goals for the next year and the next five years reflect our commitment to creating meaningful and transformational changes in the lives of individuals and communities impacted by malaria and other tropical diseases. Our goals are as follows:

Next Year (Year 1):

1. Deployment in Underserved Communities: By the end of the next year, we aim to deploy the eaza LABORATORY solution in at least 1 underserved community across Nigeria in all her 774 local government area, providing access to accurate and timely malaria diagnosis for over 1,000,000 individuals. This will be achieved through strategic partnerships with local healthcare providers, NGOs, and governmental agencies, ensuring that the solution directly reaches those most in need.

2. Policy Impact and Recognition: Within the next year, we aim to secure the endorsement and recognition of the eaza LABORATORY solution by key stakeholders in the healthcare and public health sectors, including governmental authorities and international health organizations. By actively engaging with policymakers and advocating for evidence-based policy decisions, we seek to create a conducive regulatory environment that supports the widespread adoption of AI-driven healthcare technologies in the fight against malaria and other tropical diseases.

Next Five Years (Years 2-5):

1. Scale and Reach Expansion: Over the next five years, our primary goal is to scale the eaza LABORATORY solution across Nigeria and expand its reach to other regions within Africa heavily affected by malaria. We aim to provide reliable diagnostic services to over 1 million individuals annually, significantly reducing mortality rates associated with malaria and other tropical diseases. This will involve establishing sustainable partnerships with regional healthcare networks and international aid organizations to ensure the equitable distribution and accessibility of the solution.

2. Capacity Building and Sustainable Healthcare Infrastructure: By the end of the fifth year, we envision the establishment of sustainable healthcare infrastructure in the communities we serve, with a focus on capacity building for local healthcare professionals and the integration of AI-driven diagnostic technologies into existing healthcare systems. Through comprehensive training programs, knowledge-sharing initiatives, and technology transfer partnerships, we aim to empower local communities to take ownership of their healthcare needs and promote the long-term sustainability of the eaza LABORATORY solution.

To achieve these impact goals, we will continue to prioritize community engagement, foster strategic partnerships, and advocate for evidence-based policy decisions that prioritize the well-being and health of underserved communities. Our commitment to innovation, sustainability, and equitable healthcare access will remain at the forefront of our efforts as we strive to create a transformative impact on the lives of individuals and communities affected by malaria and other tropical diseases.

Full-time staff = 3

Part-time staff = 2

Contractors or other workers = 3

1 year and 11 months. I actively started working on eaza LABORATORY idea and engaging in on-field research since November 2021. However, I was able to pitch my idea to my department heads at the University of Port Harcourt Teaching Hospital in January 2023 and secured their approval to build this solution.

Diversity, equity, and inclusivity are fundamental values that underpin our approach to creating a meaningful and sustainable impact through the eaza LABORATORY solution. We recognize the importance of fostering a culture of diversity and inclusivity within our team and in the communities we serve. Our approach to incorporating diversity, equity, and inclusivity into our work encompasses the following key aspects:

Gender diversity in our core team is balanced and women orientated with 62.5% of team members being women.

Diversity within the Leadership Team: Our leadership team is led by a woman and also comprises of other individuals from diverse backgrounds, including professionals with expertise in healthcare (including Medical Doctors, Registered Nurses, Pharmacist, Medical Laboratory Scientists, Medical Laboratory Technicians, healthcare Policy Makers), technology (Data analysts, Blockchain developer, AI developer) and community development (Community Healthcare Policy Maker). We recognize the value of diverse perspectives and experiences in driving innovation and addressing complex healthcare challenges. Our team members bring a rich array of cultural insights, professional expertise, and a shared commitment to improving healthcare access and outcomes for underserved communities.

Goals for Diversity, Equity, and Inclusivity: Our team is committed to fostering a diverse, equitable, and inclusive work environment that values and respects the contributions of all team members. We have set clear goals for enhancing diversity within our team by actively recruiting individuals from diverse backgrounds with the goal of building a women team and fostering an inclusive workplace culture that encourages open dialogue, collaboration, and mutual respect from all gender. By prioritizing diversity in our recruitment processes and promoting an inclusive team environment, we aim to leverage the collective strengths and talents of our team members to drive innovative solutions that address the complex healthcare challenges faced by underserved communities.

Actions Taken for Inclusivity: To promote inclusivity in our work, we have implemented various initiatives, including diversity training programs, cultural sensitivity workshops, and open forums for team members to share their perspectives and experiences. These initiatives foster a culture of respect, empathy, and understanding, enabling team members to collaborate effectively and contribute to the development of solutions that are reflective of the diverse needs and perspectives of the communities we serve. Additionally, we actively engage with community leaders, stakeholders, and local organizations to ensure that our work is informed by the unique cultural contexts and aspirations of the communities we aim to empower.

By prioritizing diversity, equity, and inclusivity within our team and in our engagement with the communities we serve, we are committed to fostering a culture of innovation, empathy, and mutual respect that drives our collective efforts to create sustainable and impactful solutions for the betterment of healthcare outcomes in underserved communities.

Our operational model and plan for delivering impactful outcomes through the eaza LABORATORY solution are structured around a comprehensive approach that integrates key elements of project management, stakeholder engagement, and resource acquisition. Our operational model is designed to ensure the efficient and effective implementation of the solution, with a focus on scalability, sustainability, and measurable impact. Key aspects of our operational model and plan include:

Team Organization: Our team is organized into specialized units, including a research and development team, a data analytics team, a community engagement team, and a project management team. Each unit is led by experienced professionals with a diverse skill set and expertise in their respective fields. This organizational structure enables us to streamline operations, foster cross-functional collaboration, and leverage the collective knowledge and expertise of our team members to drive the successful implementation of the eaza LABORATORY solution.

Stakeholder Engagement Strategy: Our stakeholder engagement strategy involves establishing strong partnerships with key stakeholders, including local healthcare providers, community leaders, governmental agencies, and international aid organizations. We prioritize regular communication, active participation, and collaborative decision-making to ensure that the solution's development and implementation are aligned with the specific needs and priorities of the communities we serve. By fostering meaningful partnerships and engaging stakeholders throughout the project lifecycle, we aim to build a sustainable ecosystem that supports the long-term success and impact of the eaza LABORATORY solution.

Resource Acquisition Plan: To access the tools and resources needed for the successful development and implementation of the eaza LABORATORY solution, we have established strategic partnerships with leading technology providers such as Amazon Web Services and Topl Blockchain, research institutions such as the University of Port Harcourt Teaching Hospital Research and Innovation Department, and other relevant healthcare organizations. Our resource acquisition plan focuses on securing the necessary technological infrastructure, data analytics tools, and healthcare resources to support the scalability and sustainability of the solution, ensuring that it continues to deliver impactful outcomes over the long term.

By adhering to our robust operational model and plan, we are confident in our ability to deliver measurable impact through the eaza LABORATORY solution, fostering improved healthcare access and outcomes for underserved communities and contributing to the broader global efforts to combat malaria and other tropical diseases.

eaza LABORATORY will operate as a Social Enterprise applying business solutions to address social problems. Our ultimate goal is to achieve sustainability by enabling non-profits to support themselves financially in innovative ways instead of relying solely on grants and donations. Since there are no shareholders the profits from this social enterprise are completely re-invested in our work.

Our plan for achieving financial sustainability is centered on a multifaceted approach that encompasses diversified revenue streams, strategic partnerships, and sustainable business models. We recognize the importance of establishing a robust financial framework that can support the continued development, implementation, and scaling of the eaza LABORATORY solution, while also ensuring our long-term financial viability and independence. Our plan for becoming financially sustainable includes the following key strategies:

Grants and Donations: In the initial stages, we will continue to actively pursue grants and donations from international aid organizations, philanthropic foundations, and governmental agencies that share our vision and commitment to improving healthcare outcomes in underserved communities. These funds will be directed towards research and development, capacity building initiatives, and the deployment of the eaza LABORATORY solution in targeted communities, allowing us to achieve our immediate impact goals and establish a strong foundation for long-term sustainability.

Product and Service Sales: As the eaza LABORATORY solution gains traction and establishes its presence within the healthcare sector, we plan to generate revenue through the sale of products and services, including licensing fees for the use of our AI-powered diagnostic software and data analytics tools. By offering customizable solutions and value-added services to healthcare institutions, research organizations, and governmental agencies, we aim to create a sustainable revenue stream that can supplement our funding sources and support ongoing research and development efforts.

Partnerships and Service Contracts: We will actively seek partnerships and service contracts with governmental agencies, healthcare providers, and international organizations to provide specialized diagnostic services, data analytics, and capacity building programs tailored to their specific healthcare needs. By leveraging these strategic partnerships and service contracts, we aim to diversify our revenue streams and establish long-term collaborations that foster mutually beneficial outcomes and sustainable growth.

Investment Capital and Commercialization: In the long term, we plan to explore opportunities for raising investment capital from private investors and venture capital firms that are aligned with our mission and vision. This capital will be instrumental in scaling our operations, expanding our market reach, and commercializing the eaza LABORATORY solution for broader global adoption. By exploring commercialization opportunities and tapping into the growing demand for AI-driven healthcare technologies, we aim to generate sustainable returns that will support our continued innovation and impact-driven initiatives.

Through the strategic implementation of these revenue-generating strategies, we are confident in our ability to achieve financial sustainability and ensure the long-term success and impact of the eaza LABORATORY solution, fostering improved healthcare access and outcomes for underserved communities and contributing to the global fight against malaria and other tropical diseases.

Our current operating cost incurred so far developing this project is around 12,350 USD.

Our current operating costs are primarily associated with research and development, community engagement initiatives, and initial technological infrastructure development. These costs include expenditures for personnel, research equipment, data acquisition, and community outreach activities. Based on our current operations, our estimated operating costs for the next year are projected to increase due to planned expansions and the deployment of the eaza LABORATORY solution in targeted communities. Our anticipated operating costs for the next year are as follows:

1. Personnel Expenses: This includes salaries, benefits, and training costs for our research and development team, data analytics experts, community engagement specialists, and administrative staff. Estimated human capital costs account for approximately 14.77% of our total operating expenses.

2. Research and Development Costs: These expenses encompass the procurement of research equipment, software development tools, and data acquisition resources necessary for enhancing the capabilities of the eaza LABORATORY solution. Research and development costs account for approximately 75.82% of our total operating expenses.

3. Community Engagement Initiatives: This includes the costs associated with organizing community workshops, health camps, and educational programs aimed at promoting awareness and understanding of the eaza LABORATORY solution among the target communities. Community engagement costs account for approximately 4.71% of our total operating expenses.

4. Technological Infrastructure Maintenance: These expenses encompass the upkeep and maintenance of our technological infrastructure, including server maintenance, software updates, and security measures to ensure the integrity and reliability of the eaza LABORATORY solution.

Based on our projected expansion and scaling plans, we anticipate an overall increase of approximately 315.9% in our operating costs for the next year. This increase accounts for additional staffing requirements, research and development investments, and expanded community engagement initiatives to support the successful deployment and adoption of the eaza LABORATORY solution in underserved communities across Nigeria.

Our comprehensive budgeting and financial planning strategies aim to ensure that our projected operating costs are managed effectively, allowing us to maintain the quality and effectiveness of our operations while scaling our impact and achieving our long-term goals for improving healthcare access and outcomes for underserved communities.

We have been able to estimate next year's costs when factoring in many expenses to be incurred from building and implementing our solution to around 53,145 USD.

Based on our projected operating costs and expansion plans for 2024, we are seeking funding in the amount of 53, 145 USD to continue our work and further advance the deployment and impact of the eaza LABORATORY solution. We selected this funding amount based on a comprehensive assessment of our anticipated expenses, including research and development, community engagement initiatives, and technological infrastructure investments, as well as the need for additional staffing and capacity-building programs to support our planned expansion efforts. The requested funding will be utilized for the following key purposes:

1. Research and Development: A significant portion of the funding will be allocated towards enhancing the capabilities of the eaza LABORATORY solution through ongoing research and development initiatives. This includes investing in advanced AI algorithms, data analytics tools, and image processing techniques that will further improve the accuracy and efficiency of malaria parasite detection and analysis.

2. Community Engagement and Capacity Building: A portion of the funding will be utilized to support community engagement initiatives and capacity-building programs aimed at promoting awareness, education, and training on the use of AI-driven healthcare technologies. These initiatives will empower local healthcare professionals and community members with the knowledge and skills necessary to effectively leverage the eaza LABORATORY solution and contribute to improved healthcare outcomes in their respective communities.

3. Technological Infrastructure Investments: A portion of the funding will be dedicated to upgrading and maintaining our technological infrastructure, including server maintenance, software updates, and data security measures. This investment is crucial for ensuring the reliability, scalability, and security of the eaza LABORATORY solution, especially as we scale our operations and expand our reach to serve more communities in Nigeria and across Africa.

By carefully considering our operational requirements and the anticipated impact of our work, we have determined that the requested funding highlighted below will enable us to effectively execute our planned initiatives, achieve our impact goals, and continue making significant strides in the fight against malaria and other tropical diseases. We are committed to utilizing the funding efficiently and transparently, ensuring that every dollar is maximized to create sustainable and meaningful change in the healthcare landscape of underserved communities.

1. Personnel (including salary, fringe benefits, training, or other direct compensation) - 7,850 USD

2. Subcontracts - 3,500 USD

3. Capital Assets/Equipment - 17,945 USD

4. Travel - 8,500 USD

5. Supplies - 10,350 USD

6. Other Expenses - 5,000 USD

TOTAL - 53,145 USD

Over 75.82% of requested fund will be spent on software development, and training of healthcare laboratory scientists and technicians on use of software, hardware components such as desktop computers, high resolution digital cameras, for setting up data collection across designated healthcare facilities through which data will be collected and through which healthcare facilities can access eaza LABORATORY and report data.

The end goal and strategy are to reduce financial impact and burden on partnering healthcare facilities and on the patients themselves, ensure consistent capturing and reporting of both qualitative and quantitative data.

I believe that participation in the Cure Residency would be an invaluable opportunity that could significantly accelerate the development and implementation of the eaza LABORATORY solution, ultimately amplifying its impact on healthcare outcomes in underserved communities. Several aspects of the Cure Residency align closely with our current needs and long-term goals, and we are particularly excited about the following aspects of the program:

1. Seed Funding: The provision of seed funding would enable us to further invest in research and development, enhance our technological infrastructure, and scale our operations to reach a wider audience. This financial support would be instrumental in expediting the deployment of the eaza LABORATORY solution and facilitating its integration into existing healthcare systems, ultimately fostering improved diagnostic capabilities and healthcare access for underserved communities.

2. Mentorship and Educational Programming: Access to mentorship from industry experts and educational programming tailored to the specific needs of healthcare technology startups would provide us with invaluable guidance and insights that could inform our strategic decision-making and product development initiatives. Mentorship from seasoned professionals would offer us the opportunity to gain valuable perspectives on navigating the complexities of the healthcare sector, while educational programming would empower us with the knowledge and skills needed to address key challenges and seize emerging opportunities within the industry.

3. Lab Space and Networking Opportunities: The provision of dedicated lab space would offer us a collaborative environment where we can further refine our AI-driven diagnostic solutions and conduct essential research and testing activities. Moreover, the networking opportunities facilitated by the Cure Residency would allow us to connect with like-minded entrepreneurs, industry leaders, and potential collaborators, fostering meaningful partnerships and paving the way for future collaborations and knowledge-sharing initiatives that can amplify the impact of the eaza LABORATORY solution.

4. Access to Experts in Healthcare Technology: Engaging with experts in healthcare technology through the Cure Residency would provide us with critical insights and best practices for integrating AI solutions into the healthcare ecosystem, ensuring that our solution adheres to industry standards and regulatory requirements. This access to expert knowledge would enable us to refine our solution and address any potential challenges or gaps in our approach, ultimately positioning the eaza LABORATORY solution for sustainable growth and long-term success in the healthcare technology market.

Overall, participation in the Cure Residency would not only provide us with the essential resources and support needed to advance our work but would also enable us to contribute to a dynamic ecosystem of healthcare innovation, fostering collaboration, and collective efforts to address pressing healthcare challenges and improve patient outcomes on a global scale.